
Juan Francisco SÃ;nchez Ãvila

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4615472/publications.pdf Version: 2024-02-01



Juan Francisco SÃinchez

#	Article	IF	CITATIONS
1	AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Annals of Hepatology, 2008, 7, 350-357.	0.6	187
2	Trends and projections of hepatitis C virus epidemiology in Latin America. Liver International, 2011, 31, 18-29.	1.9	115
3	Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology, 2002, 35, 930-936.	3.6	106
4	Diagnosis and treatment of hepatocellular carcinoma: An update. World Journal of Hepatology, 2015, 7, 362.	0.8	103
5	Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Annals of Hepatology, 2006, 5, 281-288.	0.6	81
6	Etiology of Liver Cirrhosis in Mexico. Annals of Hepatology, 2004, 3, 30-33.	0.6	76
7	Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World Journal of Gastroenterology, 2008, 14, 4771.	1.4	61
8	Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases. Hepatology, 2003, 37, 1226-1227.	3.6	58
9	Pocket ultrasound device as a complement to physical examination for ascites evaluation and guided paracentesis. Internal and Emergency Medicine, 2016, 11, 461-466.	1.0	31
10	PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis. World Journal of Gastroenterology, 2010, 16, 5869.	1.4	27
11	Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review. World Journal of Gastroenterology, 2006, 12, 7826.	1.4	21
12	IFN-stimulated Gene Expression Is a Useful Potential Molecular Marker of Response to Antiviral Treatment with Peg-IFNI± 2b and Ribavirin in Patients with Hepatitis C Virus Genotype 1. Archives of Medical Research, 2011, 42, 28-33.	1.5	14
13	Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular. Revista De GastroenterologÃa De México, 2014, 79, 250-262.	0.4	13
14	Non-Alcoholic Fatty-Liver Disease in Pediatric Populations. Journal of Pediatric Endocrinology and Metabolism, 2007, 20, 1059-73.	0.4	8
15	A Genetic Variant in the Interleukin 28B Gene As a Major Predictor for Sustained Virologic Response in Chronic Hepatitis C Virus Infection. Archives of Medical Research, 2015, 46, 448-453.	1.5	8
16	Mexican Consensus on the Diagnosis and Management of Hepatitis C Infection. Annals of Hepatology, 2015, 14, S7-S48.	0.6	4
17	Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort Archives of Medical Research, 2021, 52, 713-718.	1.5	3
18	Cost efficacy and cost-benefit of treatment of hepatitis C. Annals of Hepatology, 2006, 5, S69-S73.	0.6	2

#	Article	IF	CITATIONS
19	Re-treatment with Highly Purified nIFNα in Mexican Nonresponder Patients with Chronic Genotype 1 Hepatitis C. Archives of Medical Research, 2013, 44, 444-448.	1.5	1